Y-mAbs has partnered with the leading medical and research organization, Memorial Sloan Kettering Cancer Center (MSKCC), to advance a pipeline of novel immunotherapies. MSKCC is one of 41 National Cancer Institute-designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment. The close collaboration between physicians and scientists enables MSKCC to provide patients with the best care available as they work to discover more-effective strategies to prevent, control, and, ultimately, cure cancer. MSKCC’s education programs train future physicians and scientists, and the knowledge and experience they gain at MSKCC has an impact on cancer treatment and biomedical research around the world.
Y-mAbs is currently open to new partnerships that can help facilitate the expansion of its capabilities through solid innovation and synergistic collaboration.